Anthony Kent, MD
Nephrology · Bryn Mawr, PANPI 1942685441
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,530 of the $58,323 with a category attached, or 84.9%. 25 manufacturers reported payments, led by Boehringer Ingelheim at 50.8% of the total. Among nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $268.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$30K
- Lilly USA, LLC$24K
- AstraZeneca$2K
- Bayer$427
- Travere Therapeutics, Inc.$310
- Fresenius USA Marketing, Inc.$215
- plus $2K from 19 others
What the payments were for
- Consulting fees$1,6003%
- Speaking & faculty fees$49,53085%
- Travel & lodging$2,0373%
- Food & beverage$5,1359%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 33 | $29,639 |
| Lilly USA, LLC | 46 | $23,712 |
| AstraZeneca(2 entities) | 32 | $2,412 |
| Bayer | 26 | $427 |
| Travere Therapeutics, Inc. | 9 | $310 |
| Fresenius USA Marketing, Inc. | 6 | $215 |
| Novartis | 8 | $203 |
| Aurinia Pharma U.S., Inc. | 4 | $181 |
| Amgen | 6 | $151 |
| Vifor Pharma, Inc. | 6 | $139 |
| Ardelyx, Inc. | 6 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $128 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| OPKO Pharmaceuticals, LLC | 4 | $86 |
| Calliditas Therapeutics US Inc. | 3 | $86 |
| GSK | 4 | $78 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $57 |
| Daiichi Sankyo Inc. | 2 | $57 |
| Kyowa Kirin, Inc. | 2 | $54 |
| Novo Nordisk | 2 | $47 |
| Scpharmaceuticals Inc. | 1 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Cormedix Inc. | 1 | $21 |
| Akebia Therapeutics Inc | 1 | $20 |
| Daxor Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,323 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 25 | $32,048 |
| JardianceEmpagliflozin | 29 | $27,219 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $12,213 |
| Sevelamer Carbonate | 21 | $2,502 |
| Nifedipine ErNifedipine | 23 | $1,244 |
| Calcium Acetate | 12 | $881 |
| Losartan Potassium | 44 | $518 |
| Tamsulosin Hcl | 22 | $381 |
| Torsemide | 13 | $327 |
| Amlodipine Besylate | 20 | $296 |
| Famotidine | 17 | $209 |
| Hydralazine Hcl | 17 | $174 |
| Lisinopril | 11 | $151 |
| Metoprolol Succinate | 12 | $144 |
| Furosemide | 24 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $2,412 | $44,26140 claims |
| Boehringer IngelheimJardiance | $29,639 | $27,21929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Bryn Mawr
- Sophia MoldavskyBryn Mawr$7K
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.